| Identification | Back Directory | [Name]
LY 303511 | [CAS]
154447-38-8 | [Synonyms]
LY303511, >=98%
LY-303511(Nv-128)
LY 303511; LY303511
2-(1-Piperazinyl)-8-phenyl-4H-1-benzopyran-4-one
8-Phenyl-2-(1-piperazinyl)-4H-1-benzopyran-4-one
4H-1-Benzopyran-4-one, 8-phenyl-2-(1-piperazinyl)-
8-Phenyl-2-(1-piperazinyl)-4H-1-benzopyran-4-one LY303511 | [Molecular Formula]
C19H18N2O2 | [MDL Number]
MFCD03453556 | [MOL File]
154447-38-8.mol | [Molecular Weight]
306.36 |
| Chemical Properties | Back Directory | [Boiling point ]
496.1±45.0 °C(Predicted) | [density ]
1.237±0.06 g/cm3(Predicted) | [storage temp. ]
Store at +4°C | [solubility ]
Soluble to 100 mM in 1eq. HCl and to 100 mM in DMSO | [form ]
Amber solid | [pka]
9.20±0.10(Predicted) | [color ]
amber | [InChI]
1S/C19H18N2O2/c22-17-13-18(21-11-9-20-10-12-21)23-19-15(7-4-8-16(17)19)14-5-2-1-3-6-14/h1-8,13,20H,9-12H2 | [InChIKey]
NGAGMBNBKCDCDJ-UHFFFAOYSA-N |
| Hazard Information | Back Directory | [Uses]
LY 303511 is an inactive analog of the phosphoinositide 3-kinase inhibitor LY294002. | [Definition]
ChEBI: 8-phenyl-2-(1-piperazinyl)-1-benzopyran-4-one is a N-arylpiperazine. | [Biological Activity]
Negative control compound with respect to LY 294004 (2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-onehydrochloride ) PI 3-kinase inhibitory activity. Blocks voltage-gated potassium (K v ) channels (IC 50 = 64.6 μ M) and inhibits IL-1 β -stimulated NF- κ B activation, attenuating MCP-1 expression. Anti-proliferative. | [in vivo]
Intraperitoneal administration of vehicle or LY303511 (10 mg/kg/day) is performed when tumors reach a volume of ~150 mm3, at which time 35 mice have developed a tumor. After 21 days, >15% of the mice require euthanasia because of excessive tumor growth, and these data are censored due to unreliable estimates of average tumor volume. The administration of LY303511, 10 mg/kg/day, is sufficient to inhibit PC-3 tumor growth in vivo[4]. |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|